Group One Trading, L.P. Genprex, Inc. Transaction History

Group One Trading, L.P.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.19 - $0.37 $5,585 - $10,877	29,398 Added 804.54%	33,052 $7,000
Q3 2023 Nov 09, 2023	SELL	$0.37 - $1.04 $10,661 - $29,968	-28,816 Reduced 88.75%	3,654 $1,000
Q2 2023 Aug 09, 2023	SELL	$0.74 - $1.1 $53,721 - $79,856	-72,597 Reduced 69.1%	32,470 $30,000
Q1 2023 May 12, 2023	BUY	$0.76 - $1.78 $33,981 - $79,589	44,713 Added 74.08%	105,067 $95,000
Q4 2022 Feb 09, 2023	SELL	$1.0 - $58.8 $79,668 - $4.68 Million	-79,668 Reduced 56.9%	60,354 $87,000
Q3 2022 Nov 09, 2022	SELL	$1.32 - $58.0 $23,100 - $1.02 Million	-17,500 Reduced 11.11%	140,022 $197,000
Q2 2022 Aug 11, 2022	SELL	$1.28 - $2.31 $73,126 - $131,970	-57,130 Reduced 26.62%	157,522 $219,000
Q1 2022 May 12, 2022	BUY	$1.82 - $3.5 $55,075 - $105,913	30,261 Added 16.41%	214,652 $485,000
Q4 2021 Feb 11, 2022	BUY	$1.21 - $2.7 $104,349 - $232,845	86,239 Added 87.86%	184,391 $242,000
Q3 2021 Nov 12, 2021	BUY	$2.59 - $3.36 $254,213 - $329,790	98,152 New	98,152 $263,000
Q2 2021 Aug 10, 2021	SELL	$3.11 - $4.87 $58,779 - $92,043	-18,900 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$3.66 - $7.67 $69,174 - $144,963	18,900 New	18,900 $81,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $76.8M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.